Resources for HCPs

CSL Behring provides a broad range of resources and materials to assist physicians in the treatment of Alpha-1:

Referral Forms
Samples
Test Kits
Continuing Education
Web Resources
Clinical Reprints
CSL Behring Medical Affairs
CareZ

Samples

We are pleased to provide the Alpha-1 community with the option of trying Zemaira for up to 2 weeks. Sample product is shipped to the physician's office or physician's designated healthcare facility. Our specialty pharmacy partners, Accredo and Coram (a division of Apria Healthcare), provide the nursing services and supplies for the sample program.

To obtain a sample of Zemaira for one of your patients, simply select and complete a Zemaira Product Sample Request form from either Accredo or Coram and fax it to our Customer Support group at the number shown on the form
Please note that Zemaira samples can be requested only on a per-patient basis

Zemaira Product Sample Request Forms

Should you decide to continue your patient on Zemaira, Accredo and Coram can provide you with assistance.

You will need to obtain the necessary insurance clearance and set up an infusion service with Accredo, Coram, or a healthcare facility that provides infusion services
Because it can take up to 4 weeks to complete this process, we encourage you to work with your patient to fill out the referral form of your preferred specialty pharmacy and fax it to that specialty pharmacy at the same time you fax us the Product Sample Request
- This will ensure that all of the paperwork necessary for your patient to continue on Zemaira is completed by the end of the trial period

Referral Forms

For more information about the Zemaira Sample Program, please call 1-866-ZEMAIRA (1-866-936-2472).

Test Kits

CSL Behring provides Alpha LabZ eZ Kits to make it easy for you to test and diagnose your patients with Alpha-1.

Order Alpha LabZ eZ Kits now from CSL Behring

Continuing Education

The Alpha-1 Foundation offers a CME program to help educate healthcare professionals on the standards for the diagnosis and management of Alpha-1.

Learn more about the CME program offered by the Alpha-1 Foundation

Web Resources

The Alpha-1 Foundation
Provides leadership and resources to increase research, improve health, achieve worldwide detection, and find a cure for Alpha-1. This site contains an excellent explanation of Alpha-1, provides health tips, and offers a free Alpha-1 testing kit
The American Thoracic Society
Focuses on respiratory and critical care medicine, with a long-range goal of decreasing morbidity and mortality from respiratory disorders and life-threatening acute illnesses. The Society helps to set the standards for prevention, treatment, and control of these serious diseases
Accredo
Distributes Zemaira and has the country's most extensive network of pharmacies dedicated to the treatment of Alpha-1, as well as pulmonary arterial hypertension (PAH) and disorders requiring intravenous immune globulin (IVIg) therapy
Coram
A leader in home infusion services and specialty pharmacy distribution, proudly distributing Zemaira through more than 75 locations nationwide. In addition to caring for diagnosed Alpha-1 patients and offering an extensive patient advocacy program, Coram takes an active role in promoting testing for this disease

Clinical Reprints

Select any of the following journal articles on alpha₁ antitrypsin deficiency or Zemaira that are of interest to you. CSL Behring will send your selection(s), as well as future updates on alpha₁ antitrypsin deficiency and Zemaira, via e-mail.^a

Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha₁-proteinase inhibitor, Zemaira. COPD. 2006;3:17-23.
Hogarth DK, Rachelefsky G. Screening and familial testing of patient for a₁-antitrypsin deficiency. Chest. 2008;133:981-988.
Rachelefsky G, Hogarth DK. Issues in the diagnosis of alpha1-antitrypsin deficiency. J Allergy Clin Immunol. 2008;121(4):833-838.
Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha₁-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128(3):1179-1186.
American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818-900

Please complete the fields below to receive your selected readings

(*indicates a required field)

Salutation:*
First Name:*
Last Name:*
Address Line 1:*
Address Line 2:*
City:*
State:*
ZIP Code:*
E-mail Address:*

Type in the verification word in the box below and click "Submit."

Submit Reset

Prior to submitting your information, please review our Privacy Policy.

^a This list of resources is provided as a service by CSL Behring LLC. Publication of these resources by CSL Behring does not necessarily constitute our approval or endorsement of viewpoints, inferences, or conclusions stated in or implied by the authors of these materials. Listed resources were accurate at the time of publication. CSL Behring LLC is not responsible for changes in resource information.

CSL Behring Medical Affairs Department

Get answers to all of your questions regarding Alpha-1 by contacting CSL Behring Medical Affairs:

Phone: 800-504-5434
Fax: 610-878-4007
E-mail: Contact Us

You may also send correspondence by mail to the following address:

Medical Information
North American Headquarters
CSL Behring
PO Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

CareZ™

CSL Behring makes managing the treatment of Alpha-1 as easy as possible for you and your staff through our comprehensive suite of patient support programs, CareZ.

Alpha-1 is a complicated disease with complicated patient support needs
CareZ provides resources and services to help manage the treatment of Alpha-1, while delivering the educational, physical, emotional, and financial support your patients need

Learn about all that the CareZ community has to offer you, your staff, and your patients.

The Benefits of Zemaira

See the clinical data supporting the benefits of Zemaira

Dosing Calculator

Click here to determine the proper dose for your patients based on their body weight

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira^® is indicated for chronic augmentation and maintenance therapy for adults with alpha₁-proteinase inhibitor (A₁-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A₁-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.